Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
PrEP
Market for HIV Prevention Drugs May More Than Double, Citi Says

An experimental drug from Merck & Co may lead the way in the U.S. market, Citi said. Baum estimates MK-8591 may reach sales of $7 billion in HIV. Of that total, $3.5 billion may come from pre-exposure prophylaxis, or PrEP, as the preventative treatments are called.

Published
21 July 2019
From
Bloomberg
Pharmaceutical industry
Are 2 million bottles of PrEP an empty gesture?

Gilead should either commit to providing all the doses of PrEP required for everyone who would benefit or open the market up to a range of generic manufacturers.

Published
15 July 2019
From
The Lancet HIV
The search for an HIV prevention vaccine
J&J’s Quest for Elusive HIV Vaccine Is Poised for Major Test

Johnson & Johnson is preparing to test an experimental HIV vaccine in the U.S. and Europe in a move toward developing the first immunization against the deadly disease after decades of frustration.

Published
15 July 2019
From
Bloomberg
Pharmaceutical industry
GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

GlaxoSmithKline’s ViiV Healthcare already boasts an approval for Dovato, a two-drug HIV regimen, in newly diagnosed patients. And it just added some new data that aims to at least draw level with market leader Gilead in already-treated patients.

Published
11 July 2019
From
FiercePharma
Long-acting HIV treatment
Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies. Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV.

Published
10 July 2019
From
Lyndra Therapeutics press release
Clinical trials
EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database

The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database.

Published
07 July 2019
From
Health Policy Watch
Pharmaceutical industry
What Does PrEP Cost Outside the United States?

For the past several years, doctors in the United States have watched enviously as other countries have approved generic versions of PrEP made by Mylan, Teva, and other generic drug companies. These cheaper generics have made it easier for governments to support large PrEP scale-up programs.

Published
04 July 2019
From
The Body
Pharmaceutical industry
HHS gets a new HIV prevention patent, but will the agency demand royalties from Gilead?

On Tuesday, the Department of Health and Human Services was awarded a new patent that broadly covers medicines derived from tenofovir and used to prevent HIV.

Published
03 July 2019
From
STAT
Opportunistic infections
Gilead fails to keep promise on access to lifesaving drug for people living with HIV

Pharmaceutical corporation Gilead promised to expand access at an affordable price to a drug for people with an HIV-related infection, cryptococcal meningitis. One year on, the drug is registered in only six developing countries and remains prohibitively expensive.

Published
01 July 2019
From
Médecins Sans Frontières
Pharmaceutical industry
U.S. Reps to Gilead: Did your donation of free HIV prevention drug Truvada have strings attached?

In May, Gilead pledged to donate 2.4 million bottles of its HIV drug Truvada to the U.S. government’s effort to eradicate the disease, partly by preventing new infections. But now Gilead is facing accusations that its largesse may have suspicious underpinnings. The House Oversight Committee’s chairman, Rep. Elijah E. Cummings (D-MD), and three colleagues sent a letter to Gilead demanding details about what led to the company’s generous offer.

Published
01 July 2019
From
FiercePharma
← First12345...113Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.